Author Affiliations: Duke University, Durham, North Carolina.
We agree with Friberg and colleagues that caution is always warranted in the conduct and interpretation of nonrandomized treatment comparisons. The important caveats they mention were discussed in our article.1 Additional studies are needed to define the relative treatment benefits and risks of these alternative approaches to a major ocular problem in older adults.
Curtis LH, Hammill BG, Schulman KA, Cousins SW. Systemic and Ocular Risks Associated With Therapies for Macular Degeneration: Clarification vs Confusion—Reply. Arch Ophthalmol. 2012;130(6):806-807. doi:10.1001/archophthalmol.2012.100